Codelivery of adjuvants at the primary immunization site is essential for evoking a robust immune response to neoglycoconjugates

Vaccine

Volumn 29, Issue 4, 2011, Pages 849-854

  Safari, Dodi ^a   Dekker, Huberta A Th ^a   Rijkers, Ger ^b   Snippe, Harm ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Adjuvant; Neoglycoconjugate; S. pneumoniae type 14 polysaccharide

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DIPHTHERIA TOXOID CRM197; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; PNEUMOCOCCUS POLYSACCHARIDE; QUIL A; STREPTOCOCCUS PNEUMONIAE TYPE 14 POLYSACCHARIDE; TETRASACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CD4 CD8 RATIO; CPG ISLAND; CYTOKINE PRODUCTION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BLOOD; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; IMMUNIZATION; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INJECTIONS, INTRADERMAL; LYMPH NODES; MICE; MICE, INBRED BALB C; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE;

EID: 78650530937     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.084     Document Type: Article

References (29)

1. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 1999, 17(11):1075-1081.
2. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 1998, 32(3):155-172.
3. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 2007, 5(7):505-517.
4. Klinman D.M. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol. 2006, 25(3-4):135-154.
5. Gnjatic S., Sawhney N.B., Bhardwaj N. Toll-like receptor agonists: are they good adjuvants?. Cancer J. 2010, 16(4):382-391.
6. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr. Opin. Immunol. 2010, 22(3):411-416.
7. Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. 2009, 98(4):1278-1316.
8. Vos Q., Lees A., Wu Z.Q., Snapper C.M., Mond J.J. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev. 2000, 176:154-170.
9. Lee C.J., Lee L.H., Frasch C.E. Protective immunity of pneumococcal glycoconjugates. Crit. Rev. Microbiol. 2003, 29(4):333-349.
10. DeVelasco E.A., Dekker H.A., Antal P., Jalink K.P., van Strijp J.A., Verheul A.F., et al. Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines. Vaccine 1994, 12(15):1419-1422.
11. Verheul A.F., Versteeg A.A., De Reuver M.J., Jansze M., Snippe H. Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates. Infect. Immun. 1989, 57(4):1078-1083.
12. Kudryashov V., Glunz P.W., Williams L.J., Hintermann S., Danishefsky S.J., Lloyd K.O. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(6):3264-3269.
13. Victoratos P., Yiangou M., Avramidis N., Hadjipetrou L. Regulation of cytokine gene expression by adjuvants in vivo. Clin. Exp. Immunol. 1997, 109(3):569-578.
14. Schneerson R., Fattom A., Szu S.C., Bryla D., Ulrich J.T., Rudbach J.A., et al. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL. J. Immunol. 1991, 147(7):2136-2140.
15. van de Wijgert J.H., Verheul A.F., Snippe H., Check I.J., Hunter R.L. Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution. Infect. Immun. 1991, 59(8):2750-2757.
16. Chu R.S., McCool T., Greenspan N.S., Schreiber J.R., Harding C.V. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect. Immun. 2000, 68(3):1450-1456.
17. Lefeber D.J., Benaissa-Trouw B., Vliegenthart J.F., Kamerling J.P., Jansen W.T., Kraaijeveld K., et al. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect. Immun. 2003, 71(12):6915-6920.
18. Safari D., Dekker H.A., Joosten J.A., Michalik D., de Souza A.C., Adamo R., et al. Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14. Infect. Immun. 2008, 76(10):4615-4623.
19. Pullen G.R., Fitzgerald M.G., Hosking C.S. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 1986, 86(1):83-87.
20. Jansen W.T., Vakevainen-Anttila M., Kayhty H., Nahm M., Bakker N., Verhoef J., et al. Comparison of a classical phagocytosis assay and a flow cytometry assay for assessment of the phagocytic capacity of sera from adults vaccinated with a pneumococcal conjugate vaccine. Clin. Diagn. Lab Immunol. 2001, 8(2):245-250.
21. Burne M.J., Daniels F., El G.A., Mauiyyedi S., Colvin R.B., O'Donnell M.P., et al. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J. Clin. Invest. 2001, 108(9):1283-1290.
22. Katayama S., Oda K., Ohgitani T., Hirahara T., Shimizu Y. Influence of antigenic forms and adjuvants on the IgG subclass antibody response to Aujeszky's disease virus in mice. Vaccine 1999, 17(20-21):2733-2739.
23. von Hunolstein C., Mariotti S., Teloni R., Alfarone G., Romagnoli G., Orefici G., et al. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine 2001, 19(23-24):3058-3066.
24. Svetic A., Finkelman F.D., Jian Y.C., Dieffenbach C.W., Scott D.E., McCarthy K.F., et al. Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J. Immunol. 1991, 147(7):2391-2397.
25. Svetic A., Jian Y.C., Lu P., Finkelman F.D., Gause W.C. Brucella abortus induces a novel cytokine gene expression pattern characterized by elevated IL-10 and IFN-gamma in CD4+ T cells. Int. Immunol. 1993, 5(8):877-883.
26. Randall T.D., Lund F.E., Brewer J.W., Aldridge C., Wall R., Corley R.B. Interleukin-5 (IL-5) and IL-6 define two molecularly distinct pathways of B-cell differentiation. Mol. Cell. Biol. 1993, 13(7):3929-3936.
27. Diehl S., Chow C.W., Weiss L., Palmetshofer A., Twardzik T., Rounds L., et al. Induction of NFATc2 expression by interleukin 6 promotes T helper type 2 differentiation. J. Exp. Med. 2002, 196(1):39-49.
28. Diehl S., Anguita J., Hoffmeyer A., Zapton T., Ihle J.N., Fikrig E., et al. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity 2000, 13(6):805-815.
29. Trinchieri G., Pflanz S., Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19(5):641-644.